Advantage Alpha Capital Partners’s Health Catalyst HCAT Stock Holding History

Advantage Alpha Capital Partners’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-113,658	Closed	-$4.5M	–	130
2021 Q4	$4.5M	Buy	113,658 +33,450	+42%	+$1.52M	0.64%	74
2021 Q3	$4.01M	Buy	80,208 +1,370	+2%	+$74.7K	0.73%	73
2021 Q2	$4.38M	Buy	78,838 +3,022	+4%	+$161K	0.84%	58
2021 Q1	$3.55M	Buy	75,816 +11,310	+18%	+$548K	0.75%	71
2020 Q4	$2.81M	Sell	64,506 -44,821	-41%	-$1.65M	0.61%	74
2020 Q3	$4M	Buy	109,327 +15,144	+16%	+$514K	0.92%	50
2020 Q2	$2.75M	Buy	+94,183	New	+$2.6M	0.64%	77

Other funds holding HCAT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Advantage Alpha Capital Partners's HCAT Position: Q1 2022 in Review

Advantage Alpha Capital Partners sold out of Health Catalyst (HCAT) in Q1 2022, closing a stake of 113,658 shares — an estimated $4.5M sold.

Advantage Alpha Capital Partners first reported a position in HCAT in Q2 2020 and held it in 7 quarters. The position peaked at $4.5M in Q4 2021. 185 funds tracked by Wall St. Rank hold HCAT as of Q1 2022.

Advantage Alpha Capital Partners reported no remaining Health Catalyst position as of Q1 2022 after selling out during the quarter.
Advantage Alpha Capital Partners sold 113,658 Health Catalyst shares in Q1 2022, an estimated $4.5M.
Advantage Alpha Capital Partners first reported a position in Health Catalyst in Q2 2020 and held it in 7 quarters.
Advantage Alpha Capital Partners's Health Catalyst position peaked at $4.5M in Q4 2021.
185 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2022.

Based on Advantage Alpha Capital Partners's 13F filing for Q1 2022, filed 16 May 2022.